Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9151143 | 0.93 | TSHR (0.47) | KMT2APTGS1PTGS2MEN1GAA | |
| SCHEMBL7416853 | 0.93 | TSHR (0.47) | KMT2APTGS1PTGS2MEN1GAA | |
| SCHEMBL19513862 | 0.93 | TSHR (0.47) | KMT2APTGS1PTGS2MEN1GAA | |
| SCHEMBL19513822 | 0.93 | TSHR (0.47) | KMT2APTGS1PTGS2MEN1GAA | |
| SCHEMBL1627525 | 0.92 | CYP1A2 (0.52) | KMT2ACYP1A2MAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL2944990 | 0.92 | TSHR (0.49) | KMT2APTGS1PTGS2MEN1TSHR | |
| SCHEMBL7104946 | 0.87 | TSHR (0.53) | KMT2AL3MBTL1MEN1GAATSHR | |
| SCHEMBL14828748 | 0.86 | KMT2A (0.53) | KMT2ACYP1A2MAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL855306 | 0.86 | TSHR (0.50) | KMT2ACYP1A2MAPK1SMN1; SMN2MEN1 | |
| Oleic Acid SCHEMBL9404725 | 0.86 | PPARG (0.55) | KMT2ACYP1A2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660857-B2 | Reuse of carpet wastes | DSM N.V. (NL) | 2003-12-09 | — | — | US | claimed |
| EP-1257532-B1 | PROCESS FOR THE PREPARATION OF $g(e)-CAPROLACTAM | DSM IP ASSETS BV (NL) | 2003-09-10 | — | — | EP | claimed |
| US-20030065169-A1 | Process for the preparation of epsilon-caprolactam | DSM N.V. | 2003-04-03 | — | — | US | claimed |
| EP-1257532-A1 | PROCESS FOR THE PREPARATION OF $g(e)-CAPROLACTAM | DSM N.V. (NL) | 2002-11-20 | — | — | EP | claimed |
| WO-2001056984-A1 | PROCESS FOR THE PREPARATION OF ε-CAPROLACTAM | DSM N.V. (NL) | 2001-08-09 | — | — | WO | claimed |
| EP-1122241-A1 | Process for the preparation of epsilon-caprolactam | DSM N.V. (NL) | 2001-08-08 | — | — | EP | claimed |
| CN-1187324-C | Proces for the preparation of & epsii-caprolactam | DSM IP ASSETS BV (NL) | 2005-02-02 | — | — | CN | disclosed |
| US-6660857-B2 | Reuse of carpet wastes | DSM N.V. (NL) | 2003-12-09 | — | — | US | disclosed |
| US-6660857-B2 | Reuse of carpet wastes | DSM N.V. (NL) | 2003-12-09 | — | — | US | disclosed |
| EP-1257532-B1 | PROCESS FOR THE PREPARATION OF $g(e)-CAPROLACTAM | DSM IP ASSETS BV (NL) | 2003-09-10 | — | — | EP | disclosed |
| CN-1419540-A | Process for preparing epsilon-caprolactam | DSM NV (NL) | 2003-05-21 | — | — | CN | disclosed |
| US-20030065169-A1 | Process for the preparation of epsilon-caprolactam | DSM N.V. | 2003-04-03 | — | — | US | disclosed |
| US-20030065169-A1 | Process for the preparation of epsilon-caprolactam | DSM N.V. | 2003-04-03 | — | — | US | disclosed |
| EP-1257532-A1 | PROCESS FOR THE PREPARATION OF $g(e)-CAPROLACTAM | DSM N.V. (NL) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001056984-A1 | PROCESS FOR THE PREPARATION OF ε-CAPROLACTAM | DSM N.V. (NL) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001056984-A1 | PROCESS FOR THE PREPARATION OF ε-CAPROLACTAM | DSM N.V. (NL) | 2001-08-09 | — | — | WO | disclosed |
| EP-1122241-A1 | Process for the preparation of epsilon-caprolactam | DSM N.V. (NL) | 2001-08-08 | — | — | EP | disclosed |
| EP-1122241-A1 | Process for the preparation of epsilon-caprolactam | DSM N.V. (NL) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065169-A1 | Process for the preparation of epsilon-caprolactam | MCCC2, ACMSD, PCCA | KMT2A 2947/4885CYP1A2 3399/4885MAPK1 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.